Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide - An overview

被引:383
作者
Ignarro, LJ
Napoli, C
Loscalzo, J
机构
[1] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Evans Dept Med, Boston, MA 02118 USA
[2] Univ Calif Los Angeles, Ctr Hlth Sci, Nitr Oxide Res Grp, Los Angeles, CA 90024 USA
[3] Univ Naples Federico II, Dept Med, Naples, Italy
[4] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
关键词
oxidant stress; cardiovascular pharmacology; endothelium; vascular type; nitric oxide;
D O I
10.1161/hh0102.102330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide (NO) mediates multiple physiological and pathophysiological processes in the cardiovascular system. Pharmacological compounds that release NO have been useful tools for evaluating the pivotal role of NO in cardiovascular physiology and therapeutics. These agents constitute two broad classes of compounds, those that release NO or one of its redox congeners spontaneously and those that require enzymatic metabolism to generate NO. In addition, several commonly used cardiovascular drugs exert their beneficial action, in part, by modulating the NO pathway. Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 107 条
[11]  
De Tejada IS, 1999, J PHARMACOL EXP THER, V290, P121
[12]   NO-aspirins: a class of new antiinflammatory and antithrombotic agents [J].
del Soldato, P ;
Sorrentino, R ;
Pinto, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) :319-323
[13]   Dual mode of action of dihydropyridine calcium antagonists - A role for nitric oxide [J].
Dhein, S ;
Salameh, A ;
Berkels, R ;
Klaus, W .
DRUGS, 1999, 58 (03) :397-404
[14]  
Ding YX, 2000, J PHARMACOL EXP THER, V292, P606
[15]   Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta [J].
Ellis, A ;
Li, CG ;
Rand, MJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (02) :315-322
[16]   Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase [J].
Endres, M ;
Laufs, U ;
Huang, ZH ;
Nakamura, T ;
Huang, P ;
Moskowitz, MA ;
Liao, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8880-8885
[17]  
Ettenson DS, 2000, VASC MED, V5, P97
[18]  
Ewing JF, 1997, J PHARMACOL EXP THER, V283, P947
[19]   The use of nitric oxide donors in pharmacological studies [J].
Feelisch, M .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) :113-122
[20]   Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones [J].
Fernández-Tomé, P ;
Lizasoain, I ;
Leza, JC ;
Lorenzo, P ;
Moro, MA .
NEUROPHARMACOLOGY, 1999, 38 (09) :1307-1315